Table 4.

Summary of antiviral treatment modalities versus end of treatment PCR negativity.

Treatment	End of treatment COVID-19 negative (N: 71)	End of treatment COVID-19 positive (N: 19)	p
Any favipiravir	68 (95.7%)	17 (89.5%)	0.286
No favipiravir	3 (4.3%)	2 (10.5%)
Up to 10 day favipiravir	6 (8.5%)	7 (36.9%)	0.002
Up to 5 day favipiravir	62 (87.3%)	10 (52.6%)
No favipiravir	3 (4.2%)	2 (10.5%)
Up to 10 day favipiravir	6 (8.5%)	7 (36.9%)	< 0.001
Up to 5 day favipiravir	62 (87.3%)	10 (52.6%)
Up to 5 day favipiravir	62 (87.3%)	10 (52.6%)	0.119
No favipiravir	3 (4.2%)	2 (10.5%)
Up to 10 day favipiravir	6 (8.5%)	7 (36.9%)	0.598
No favipiravir	3 (4.2%)	2 (10.5%)
COVID-19 convalescent plasma	12 (16.9%)	0 (0%)	0.054
No plasma	59 (83.1%)	19 (100%)
IV immunoglobulin	4 (5.6%)	4 (21.1%)	0.035
No IV immunoglobulin	67 (94.4%)	15 (78.9%)
Hydroxychloroquine	6 (8.5%)	2 (10.5%)	0.777
No hydroxychloroquine	65 (91.5%)	17 (89.5%)
Famotidine	11 (15.5%)	5 (26.3%)	0.273
No famotidine	60 (84.5%)	14 (73.7%)
Remdesivir	0 (0%)	1 (5.3%)	NC
No remdesivir	71 (100%)	18 (94.7%)

NC not calculated due to low n.